Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) reported a share repurchase on 23 June 2026, acquiring 338,800 H shares on the Hong Kong Stock Exchange at prices between HKD 5.99 and HKD 6.20. The outlay totalled HKD 2.05 million, implying a volume-weighted average cost of HKD 6.05 per share.

Prior to the transaction, the company had 241.49 million issued shares (excluding treasury) and 3.91 million treasury shares. Post-buyback, the number of issued shares outstanding decreased by 0.14% to 241.15 million, while treasury holdings rose to 4.25 million. The total issued share count remained unchanged at 245.40 million because the repurchased shares are being held in treasury rather than cancelled.

The repurchase forms part of a mandate approved on 15 June 2026 that authorises Jiuyuan Gene to buy back up to 24.15 million shares. Including the latest transaction, 0.37 million shares—equivalent to 0.15% of the issued shares at the date of the mandate—have been repurchased under this authority.

Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share disposals until 23 July 2026.